Drug Repurposing and Repositioning: March 19, 2026

Drug repurposing continues to offer significant opportunities to bring treatments to patients faster and at lower development risk. However, success increasingly depends on getting regulatory strategy, reimbursement pathways, and IP protection right from the outset.

This webinar brings together senior experts in regulatory science, health technology assessment (HTA), reimbursement, and IP strategy to explore how repurposing programmes can be structured to maximize the likelihood of approval, funding, and commercial viability across Europe.

The discussion will focus on practical considerations, common pitfalls, and strategic decisions that sponsors, universities, and companies must address when advancing repurposed drugs toward registration and reimbursement.

Key topics

• Regulatory and HTA considerations specific to drug repurposing
• Reimbursement challenges and evidence expectations in Europe
• Designing development strategies that align with regulatory and payer requirements
• IP protection strategies for repurposed products
• Leveraging patents, data exclusivity, and lifecycle management
• Common reasons repurposing programmes fail — and how to avoid them.

Who should attend

This webinar is particularly relevant for:

• Pharmaceutical and biotech companies
• University hospitals and technology transfer offices
• Drug repurposing consortia and research programmes
• Investors and strategic partners in life sciences
• Legal, regulatory, and market access professionals.

The session is designed to be informative, practical, and interactive, with a focus on real-world decision-making rather than theory.

For more information and to register, click here.

← Back to News

You may also like…